Luteinizing Hormone-Releasing Hormone Receptor (LHRH-R) and Cholecystokinin Receptor (CCK2-R)-Targeted Radiotherapetuics

Technology Readiness Level: 4
  • Technology Readiness Level: 4


Researchers at Purdue University have discovered a method of making radiotherapeutic conjugates comprising targeting ligands of LHRH-R and CCK2-R, receptors that are overexpressed in cancers but have restricted expression in healthy cells. Both LHRH-R and CCK2-R receptors play a role in growth and proliferation of cancers. Conventional cancer therapeutic drugs lack the ability to differentiate between cancer cells and healthy cells, which results in mild to severe adverse effects such as nausea, hair loss, myelosuppression, and cardiotoxicity. By targeting receptors that are overexpressed in cancer cells, the Purdue researchers have created a cancer-selective therapeutic technique.



  • Cancer-selective
  • Fewer adverse effects

Potential Applications

  • Cancer therapeutic drugs (possible inclusion into a therapeutic regime

Contact Information

Name: Brooke L L. Beier


Phone: 810-571-2387